Company / Cash & Equivalents
Dare Bioscience, Inc. Cash & Equivalents History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$24.7M
FY2025
5-year range
$5.5M / $34.7M
FY2021-FY2025
Trend
+57.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $10M to $25M over the past 2 years.
Based on SEC 10-K filings.
$25M in FY2025 with a 10-year CAGR of +16.2%.
Improved from $10M to $25M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -10.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- +16.2%
Key checks
Key Insights
- 3-year CAGR of -10.7%, indicating a declining trend.
- In FY2025, cash & equivalents increased 57.4% year-over-year.
- Peak cash & equivalents was recorded in FY2022.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -2.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $24.7M | +57.4% |
| FY2024 | $15.7M | +49.8% |
| FY2023 | $10.5M | -69.8% |
| FY2022 | $34.7M | +531.7% |
| FY2016 | $5.5M | +0.0% |
| FY2015 | $5.5M | -67.2% |
| FY2014 | $16.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026